RBx 2258

Drug Profile

RBx 2258

Alternative Names: Pamirosin; Parvosin; SPM 969

Latest Information Update: 13 Sep 2006

Price : $50

At a glance

  • Originator Ranbaxy Laboratories
  • Class Urologics
  • Mechanism of Action Alpha 1 adrenergic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Benign prostatic hyperplasia

Most Recent Events

  • 06 Nov 2004 Suspended - Phase-II for Benign prostatic hyperplasia in India (PO)
  • 06 Nov 2004 Suspended - Phase-II for Benign prostatic hyperplasia in South Africa (PO)
  • 06 Nov 2004 Suspended - Phase-I for Benign prostatic hyperplasia in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top